TransThera Sciences (Nanjing), Inc. Announces First Patient Dosed in Confirmatory Phase III Clinical Trial of Tinengotinib

Key Highlights for Investors

• First Patient Dosed: TransThera Sciences (Nanjing), Inc. has announced that the first patient has been dosed in its confirmatory Phase III clinical trial for Tinengotinib (TT-00420), a core product targeting advanced cholangiocarcinoma (CCA).
• Trial Details: The trial is a randomized, controlled, open-label, multi-center Phase III clinical study conducted in China. It aims to compare Tinengotinib’s efficacy and safety against standard chemotherapy in patients with unresectable advanced or metastatic intrahepatic CCA harboring FGFR2 fusion/rearrangement or mutation who have relapsed or progressed following first-line systemic therapy.
• Market Opportunity: The global CCA drug market is projected to grow from USD2 billion in 2024 to USD3.2 billion by 2027. Notably, around 25.2% of CCA patients present with FGFR alterations, indicating a substantial addressable market.
• Unmet Clinical Need: According to Cancer Treatment Reviews (2023), patients with CCA often develop acquired resistance after treatment with FGFR inhibitors. Tinengotinib is positioned as the world’s first and only investigational product seeking marketing approval for relapsed or refractory CCA patients who have previously been treated with FGFR inhibitors.
• Regulatory Progress: The pivotal Phase II clinical trial for Tinengotinib has been completed in China. Its New Drug Application (NDA) has already been submitted and accepted for review by the National Medical Products Administration (NMPA).
• Global Development: Tinengotinib is undergoing additional international, multi-center Phase III clinical trials overseas, expanding its potential market and regulatory reach.
• Unique Attributes: Tinengotinib is an internally discovered, NDA-stage, innovative multi-target small molecule kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Multiple clinical trials are ongoing globally, targeting not only CCA but also prostate, breast, and liver cancers.
• Regulatory Designations: Tinengotinib has received several prestigious designations:
  • Priority Review and Approval Procedure and Breakthrough Therapy Designation (BTD) from NMPA, China
  • Orphan Drug Designation (ODD) and Fast Track Designation from the FDA (US) for CCA
  • Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for biliary tract cancer
• Leadership: Dr. Frank Wu, Chairman and CEO, is leading the company, with an experienced board including executive, non-executive, and independent directors.

Potential Price-Sensitive Information

• The dosing of the first patient in the confirmatory Phase III trial marks a major milestone, demonstrating progress towards commercialization and potential revenue generation.
• Tinengotinib’s status as the world’s first investigational product for CCA patients resistant to FGFR inhibitors could provide first-mover advantage and significant market share if successfully approved.
• The acceptance of the NDA by the NMPA signals regulatory momentum and could lead to market entry in China, with implications for sales and share value.
• Multiple international regulatory designations (BTD, ODD, Fast Track) reduce approval timelines and provide strategic advantages, enhancing the likelihood of early commercialization and increased investor confidence.
• Ongoing global trials broaden potential markets, increasing the scope for future revenue streams.

Investor Considerations

Investors should note that while Tinengotinib is at an advanced stage of development and has received significant regulatory attention, commercialization depends on successful completion of clinical trials and regulatory approval. The drug addresses a critical unmet need in cholangiocarcinoma with FGFR alterations and has the potential to capture a significant share of a rapidly growing market. Any positive clinical or regulatory updates could be significant catalysts for share price movement.

A warning is issued under Rule 18A.08(3) of the Hong Kong Listing Rules: There is no assurance that Tinengotinib or other relevant products will ultimately be successfully developed and marketed by the company.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. All forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied.

View TRANSTHERA-B Historical chart here